Innate Pharma Sa Class A

Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026

Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026

Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event

Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) and 2025 Form 20-f Annual Report